Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05357833 · ClinicalTrials.gov registry record · Early Phase 1
Novel Imaging Markers in SPMS
A Early Phase 1 study of Multiple Sclerosis and Multiple Sclerosis, Secondary Progressive, sponsored by University of Utah.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT05357833 is a Early Phase 1 study of Multiple Sclerosis and Multiple Sclerosis, Secondary Progressive that has completed, run by University of Utah. The registered enrollment target is 11 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05357833, a Early Phase 1 study of Multiple Sclerosis and Multiple Sclerosis, Secondary Progressive, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot study takes the innovative approach of using ultrasmall superparamagnetic iron oxide (USPIO) nanoparticle enhanced MRI to measure activity of the innate immune system within MS lesions. Activity of innate immunity has been hypothesized as one of the critical pathologic processes underpinning neurologic worsening in progressive MS. As such, in the short term this project proposes to investigate USPIO uptake in SPMS lesions as a promising in vivo imaging biomarker for chronic-active lesions, as distinguished from chronic-inactive lesions.
Conditions Studied
Interventions
- DRUG Ferumoxytol infusion
- DRUG Gadoteridol
- DIAGNOSTIC_TEST MRI Brain and Cervical Spine
Study Locations (1)
Utah
- University of Utah Health Imaging and Neurosciences Center - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2023-09-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05357833
The ClinicalTrials.gov registry entry for NCT05357833 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (98% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 3 interventions - of which Ferumoxytol infusion is the first listed.
NCT05357833 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT05357833 about?
NCT05357833 is a clinical study titled "Novel Imaging Markers in SPMS". This pilot study takes the innovative approach of using ultrasmall superparamagnetic iron oxide (USPIO) nanoparticle enhanced MRI to measure activity of the innate immune system within MS lesions. Activity of innate immunity has been hypothesized as one of the critical pathologic processes underpinn...
What is the current status of trial NCT05357833?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 11 participants. The study started on 2022-06-01. Estimated completion is 2023-09-01.
What conditions does trial NCT05357833 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Multiple Sclerosis, Secondary Progressive, Secondary Progressive Multiple Sclerosis.
What interventions are being tested in trial NCT05357833?
The interventions under investigation include: Ferumoxytol infusion (DRUG), Gadoteridol (DRUG), MRI Brain and Cervical Spine (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05357833?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05357833 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Entire-body PET Scans for Multiple Sclerosis
RECRUITING · Early Phase 1
-
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
RECRUITING · Early Phase 1
-
Assessment of Synaptic Density in MS
RECRUITING · Early Phase 1
-
Oral FMT (Fecal Microbial Transplant) in Subjects with Multiple Sclerosis
ACTIVE NOT RECRUITING · Early Phase 1
-
Acute Effects of Walking Exercise on Brain Functioning in Multiple Sclerosis
ACTIVE NOT RECRUITING · Early Phase 1
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.